Equity Profile

JNJ

Johnson & Johnson

Health CarePharmaceuticals$632.4B

Jul15Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Johnson & Johnson (JNJ) is a leading health care company that develops and sells pharmaceuticals, medical devices, and consumer health products. With a market cap of $632 billion, it plays a crucial role in the health care sector, focusing on innovation and patient care.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, reflecting how much profit is attributed to each share.

$2.84

Revenue

Revenue figures provide insight into the company's overall sales performance and market demand for its products.

$25.0B

Wall Street expectations, options signals, track record, and call prep available with Pro.

JNJ Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.82%

Avg Stock Reaction

+1.22%

Last Quarter Recap

In Q1-2026, Johnson & Johnson reported an EPS of $2.70, beating estimates by 1.09%. The stock reacted positively, gaining 0.90% the next day.

Management Promises & Guidance

Continued focus on innovation in pharmaceuticals.
Commitment to improving operational efficiency.
Plans to expand market presence in emerging economies.

Expectations

Wall Street Expectations

Analysts expect Johnson & Johnson to report strong earnings driven by robust sales in its pharmaceutical segment. The consensus EPS estimate is $2.84, indicating confidence in the company's performance.

Bull Case

If JNJ exceeds the EPS estimate and shows strong revenue growth, it could signal a recovery in demand for its products, leading to a positive stock reaction.

Bear Case

Conversely, if the company misses EPS or revenue estimates, it may raise concerns about its growth prospects and market share, potentially leading to a negative stock reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

$2.84

EPS is a key indicator of the company's profitability and financial health, reflecting how much profit is attributed to each share.

Revenue

$25.0B

Revenue figures provide insight into the company's overall sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed $2.84, and what factors contributed to this performance?

A strong EPS could indicate robust demand and operational efficiency, which are critical for investor confidence.

What is the revenue outlook for the pharmaceutical segment?

Given the importance of pharmaceuticals to JNJ's overall business, insights into revenue growth will be closely watched.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of new product launches in the pharmaceutical segment, which could drive higher-than-expected revenue.

Supporting Evidence

Recent trends in health care spending suggest increased demand for innovative treatments.

The options market is pricing a larger move than historical averages, indicating potential for surprise.

Insider selling may reflect caution, but it does not necessarily indicate a lack of confidence in upcoming performance.

Key Risk

If pharmaceutical revenue exceeds $12 billion, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on the balance between strong pharmaceutical sales and overall market conditions.

Bull Confirmed If

An EPS of $2.90 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $2.70 would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±7.37%

Historical Avg

±1.9%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±7.4% while JNJ has averaged ±1.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

19.7%

Calls (398K)P/C Ratio: 0.92Puts (415K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If JNJ beats expectations, history suggests the stock could rise by about 1.22% on the following day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

Should JNJ miss estimates, history indicates a potential decline of around 1.22% as investors reassess growth prospects.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·3 sells

Members

House + Senate

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

R-NJThomas H. Kean JrRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches in the pharmaceutical division.
2Any commentary on market share changes in key segments.
3Insights into cost management and operational efficiency improvements.
4Guidance on revenue expectations for the next quarter.
5Responses to competitive pressures in the health care market.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Fastenal Company

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, reflecting how much profit is attributed to each share.

$2.84

Revenue

Revenue figures provide insight into the company's overall sales performance and market demand for its products.

$25.0B

Wall Street expectations, options signals, track record, and call prep available with Pro.

JNJ Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.82%

Avg Stock Reaction

+1.22%

Last Quarter Recap

In Q1-2026, Johnson & Johnson reported an EPS of $2.70, beating estimates by 1.09%. The stock reacted positively, gaining 0.90% the next day.

Management Promises & Guidance

Continued focus on innovation in pharmaceuticals.
Commitment to improving operational efficiency.
Plans to expand market presence in emerging economies.

Expectations

Wall Street Expectations

Bull Case

If JNJ exceeds the EPS estimate and shows strong revenue growth, it could signal a recovery in demand for its products, leading to a positive stock reaction.

Bear Case

Conversely, if the company misses EPS or revenue estimates, it may raise concerns about its growth prospects and market share, potentially leading to a negative stock reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

$2.84

EPS is a key indicator of the company's profitability and financial health, reflecting how much profit is attributed to each share.

Revenue

$25.0B

Revenue figures provide insight into the company's overall sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed $2.84, and what factors contributed to this performance?

A strong EPS could indicate robust demand and operational efficiency, which are critical for investor confidence.

What is the revenue outlook for the pharmaceutical segment?

Given the importance of pharmaceuticals to JNJ's overall business, insights into revenue growth will be closely watched.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of new product launches in the pharmaceutical segment, which could drive higher-than-expected revenue.

Supporting Evidence

Recent trends in health care spending suggest increased demand for innovative treatments.

The options market is pricing a larger move than historical averages, indicating potential for surprise.

Insider selling may reflect caution, but it does not necessarily indicate a lack of confidence in upcoming performance.

Key Risk

If pharmaceutical revenue exceeds $12 billion, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on the balance between strong pharmaceutical sales and overall market conditions.

Bull Confirmed If

An EPS of $2.90 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $2.70 would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±7.37%

Historical Avg

±1.9%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±7.4% while JNJ has averaged ±1.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

19.7%

Calls (398K)P/C Ratio: 0.92Puts (415K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If JNJ beats expectations, history suggests the stock could rise by about 1.22% on the following day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

Should JNJ miss estimates, history indicates a potential decline of around 1.22% as investors reassess growth prospects.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·3 sells

Members

House + Senate

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

R-NJThomas H. Kean JrRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches in the pharmaceutical division.
2Any commentary on market share changes in key segments.
3Insights into cost management and operational efficiency improvements.
4Guidance on revenue expectations for the next quarter.
5Responses to competitive pressures in the health care market.